These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 15885297)

  • 1. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
    Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
    Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
    Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
    Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
    Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
    Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
    Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.